AMRX
VENTE TOTALE: 50 000 titres (~882 000,00 $ US)
- Insiders
- Kiely John
- Total bought
- —
- Total sold
- $882,000
- Last activity
- 2026-08-13
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-16
AMRX presents a credible operational turnaround in 2025–2026, with improving margins, deleveraging progress, and a strategically sound acquisition of Kashiv BioSciences that establishes a biosimilars growth platform.
The first sentence of the analysis written for AMRX on 2026-08-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 37.6% | 36.5% | 36.1% | 35.8% | 36.7% | |
| Ebit Margin | 12.6% | 7.3% | 11.3% | 9.0% | 8.0% | |
| Ebitda Margin | 20.0% | 15.7% | 20.9% | 19.9% | 19.2% | |
| Operating Profit Margin | 14.0% | 8.9% | 8.5% | -4.3% | 7.3% | |
| Pretax Profit Margin | 4.6% | -2.0% | -1.7% | -11.2% | 1.5% | |
| Continuous Operations Profit Margin | 4.2% | -2.6% | -2.0% | -11.5% | 1.0% | |
| Net Profit Margin | 2.4% | -4.2% | -3.5% | -5.9% | 0.5% | |
| Bottom Line Profit Margin | 2.4% | -4.2% | -3.5% | -5.9% | 0.5% | |
| Current Ratio | 2.168 | 1.405 | 1.628 | 1.875 | 2.245 | |
| Quick Ratio | 1.480 | 0.863 | 0.941 | 1.170 | 1.522 | |
| Solvency Ratio | 0.081 | 0.034 | 0.043 | 0.031 | 0.068 | |
| Cash Ratio | 0.353 | 0.098 | 0.108 | 0.035 | 0.366 | |
| Price To Earnings Ratio | 54.783 | -20.842 | -12.646 | -2.314 | 68.429 | |
| Price To Earnings Growth Ratio | -0.341 | 1.000 | 0.286 | 0.002 | -0.771 | |
| Forward Price To Earnings Growth Ratio | -0.341 | 1.000 | 0.286 | 0.002 | -0.771 | |
| Price To Earnings Diluted Ratio | 57.273 | -20.842 | -12.646 | -2.314 | 68.429 | |
| Price To Earnings Diluted Growth Ratio | -0.363 | 1.000 | 0.286 | 0.002 | -0.773 | |
| Price To Book Ratio | -55.773 | -22.396 | 53.696 | 1.007 | 1.980 | |
| Price To Sales Ratio | 1.308 | 0.876 | 0.444 | 0.136 | 0.341 | |
| Price To Free Cash Flow Ratio | 14.628 | 11.118 | 3.843 | -11.782 | 3.675 | |
| Price To Operating Cash Flow Ratio | 11.613 | 8.292 | 3.074 | 4.614 | 2.950 | |
| Debt To Assets Ratio | 0.744 | 0.741 | 0.792 | 0.749 | 0.730 | |
| Debt To Equity Ratio | -38.654 | -23.732 | 139.049 | 9.534 | 7.982 | |
| Debt To Capital Ratio | 1.027 | 1.044 | 0.993 | 0.905 | 0.889 | |
| Long Term Debt To Capital Ratio | 1.028 | 1.053 | 0.992 | 0.898 | 0.883 | |
| Financial Leverage Ratio | -51.958 | -32.045 | 175.551 | 12.731 | 10.933 | |
| Working Capital Turnover Ratio | 4.059 | 5.648 | 4.022 | 2.946 | 2.438 | |
| Operating Cash Flow Ratio | 0.386 | 0.261 | 0.408 | 0.086 | 0.357 | |
| Operating Cash Flow Sales Ratio | 0.113 | 0.106 | 0.144 | 0.029 | 0.116 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.794 | 0.746 | 0.800 | -0.392 | 0.803 | |
| Debt Service Coverage Ratio | 2.256 | 0.722 | 1.162 | 1.746 | 2.336 | |
| Interest Coverage Ratio | 1.755 | 0.964 | 0.970 | -0.599 | 1.120 | |
| Short Term Operating Cash Flow Coverage Ratio | 15.758 | 0.910 | 1.621 | 0.724 | 7.899 | |
| Operating Cash Flow Coverage Ratio | 0.124 | 0.114 | 0.126 | 0.023 | 0.084 | |
| Capital Expenditure Coverage Ratio | 4.853 | 3.935 | 4.995 | 0.719 | 5.067 | |
| Dividend Paid And Capex Coverage Ratio | 4.853 | 3.935 | 4.995 | 0.719 | 5.067 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 10.555 | 11.210 | 7.431 | 7.087 | 8.331 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 37.6% | ▲1.1% | ▲1.1% |
| Ebit Margin | 12.6% | ▲5.3% | ▲2.9% |
| Ebitda Margin | 20.0% | ▲4.3% | ▲0.9% |
| Operating Profit Margin | 14.0% | ▲5.1% | ▲7.1% |
| Pretax Profit Margin | 4.6% | ▲6.6% | ▲6.4% |
| Continuous Operations Profit Margin | 4.2% | ▲6.9% | ▲6.4% |
| Net Profit Margin | 2.4% | ▲6.6% | ▲4.5% |
| Bottom Line Profit Margin | 2.4% | ▲6.6% | ▲4.5% |
| Current Ratio | 2.168 | ▲0.762 | ▲0.304 |
| Quick Ratio | 1.480 | ▲0.617 | ▲0.285 |
| Solvency Ratio | 0.081 | ▲0.047 | ▲0.029 |
| Cash Ratio | 0.353 | ▲0.255 | ▲0.161 |
| Price To Earnings Ratio | 54.783 | ▲75.625 | ▲37.301 |
| Price To Earnings Growth Ratio | -0.341 | ▼-1.342 | ▼-0.376 |
| Forward Price To Earnings Growth Ratio | -0.341 | ▼-1.342 | ▼-0.376 |
| Price To Earnings Diluted Ratio | 57.273 | ▲78.115 | ▲39.293 |
| Price To Earnings Diluted Growth Ratio | -0.363 | ▼-1.363 | ▼-0.393 |
| Price To Book Ratio | -55.773 | ▼-33.378 | ▼-51.476 |
| Price To Sales Ratio | 1.308 | ▲0.432 | ▲0.687 |
| Price To Free Cash Flow Ratio | 14.628 | ▲3.510 | ▲10.331 |
| Price To Operating Cash Flow Ratio | 11.613 | ▲3.321 | ▲5.505 |
| Debt To Assets Ratio | 0.744 | ▲0.003 | ▼-0.007 |
| Debt To Equity Ratio | -38.654 | ▼-14.922 | ▼-57.490 |
| Debt To Capital Ratio | 1.027 | ▼-0.017 | ▲0.055 |
| Long Term Debt To Capital Ratio | 1.028 | ▼-0.025 | ▲0.057 |
| Financial Leverage Ratio | -51.958 | ▼-19.913 | ▼-75.000 |
| Working Capital Turnover Ratio | 4.059 | ▼-1.590 | ▲0.236 |
| Operating Cash Flow Ratio | 0.386 | ▲0.124 | ▲0.086 |
| Operating Cash Flow Sales Ratio | 0.113 | ▲0.007 | ▲0.011 |
| Free Cash Flow Operating Cash Flow Ratio | 0.794 | ▲0.048 | ▲0.244 |
| Debt Service Coverage Ratio | 2.256 | ▲1.534 | ▲0.612 |
| Interest Coverage Ratio | 1.755 | ▲0.791 | ▲0.913 |
| Short Term Operating Cash Flow Coverage Ratio | 15.758 | ▲14.848 | ▲10.375 |
| Operating Cash Flow Coverage Ratio | 0.124 | ▲0.010 | ▲0.030 |
| Capital Expenditure Coverage Ratio | 4.853 | ▲0.917 | ▲0.939 |
| Dividend Paid And Capex Coverage Ratio | 4.853 | ▲0.917 | ▲0.939 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 10.555 | ▼-0.654 | ▲1.633 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.95B | $2.45B | $1.06B | $300.4M | $713.3M | |
| Enterprise value | $6.37B | $4.93B | $3.72B | $3.12B | $3.34B | |
| EV / Sales | 2.11x | 1.76x | 1.55x | 1.41x | 1.60x | |
| EV / Op. cash flow | 18.75x | 16.70x | 10.77x | 47.92x | 13.82x | |
| EV / Free cash flow | 23.61x | 22.40x | 13.46x | -122.36x | 17.22x | |
| EV / EBITDA | 10.55x | 11.21x | 7.43x | 7.09x | 8.33x | |
| Net debt / EBITDA | 4.02x | 5.64x | 5.31x | 6.40x | 6.55x | |
| Current ratio | 2.17x | 1.41x | 1.63x | 1.88x | 2.25x | |
| Income quality | 4.72x | -4.00x | -7.09x | -0.26x | 22.76x | |
| Graham number | — | — | — | — | $2 | |
| Graham net-net | -$8 | -$8 | -$15 | -$18 | -$17 | |
| Tax burden | 51.8% | 212.5% | 208.6% | 52.4% | 33.9% | |
| Interest burden | 36.6% | -27.0% | -14.8% | -124.0% | 18.7% | |
| Working capital | $1.03B | $458.0M | $531.3M | $659.0M | $842.9M | |
| Invested capital | $2.74B | $2.31B | $2.57B | $2.94B | $3.24B | |
| Return on assets | 2.0% | -3.3% | -2.4% | -3.4% | 0.3% | |
| Operating ROA | 11.8% | 7.2% | 5.6% | -2.5% | 3.8% | |
| Return on tangible assets | 2.9% | -5.4% | -4.2% | -6.2% | 0.5% | |
| Return on equity | -101.8% | 107.0% | -424.6% | -43.6% | 2.9% | |
| Return on invested capital | 13.8% | 9.2% | 7.2% | -3.0% | 3.0% | |
| Return on capital employed | 15.1% | 10.5% | 7.8% | -3.1% | 4.7% | |
| Earnings yield | 1.8% | -4.8% | -7.9% | -43.3% | 1.5% | |
| Free cash flow yield | 6.8% | 9.0% | 26.0% | -8.5% | 27.2% | |
| Capex / Op. cash flow | 20.6% | 25.4% | 20.0% | 139.2% | 19.7% | |
| Capex / Depreciation | 31.3% | 31.7% | 30.2% | 37.7% | 20.4% | |
| Capex / Sales | 2.3% | 2.7% | 2.9% | 4.1% | 2.3% | |
| SG&A / Sales | 17.5% | 17.1% | 18.0% | 18.1% | 17.5% | |
| R&D / Sales | 6.2% | 6.8% | 8.1% | 9.4% | 10.0% | |
| Stock comp / Sales | 1.1% | 1.0% | 1.1% | 1.4% | 0.0% | |
| Intangibles / Total assets | 31.5% | 38.0% | 42.9% | 44.6% | 44.7% | |
| Days sales outstanding | 114d | 101d | 98d | 122d | 121d | |
| Days payables outstanding | 49d | 53d | 34d | 43d | 36d | |
| Operating cycle | 231d | 227d | 237d | 259d | 256d | |
| Cash conversion cycle | 182d | 174d | 203d | 216d | 220d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+61.4%EV / Sales ▲+19.7%EV / EBITDA ▼-5.8%EV / Op. cash flow ▲+2.042Earnings yield ▲+0.066
Profitability
Return on equity ▼-2.088Return on assets ▲+0.053Return on invested capital ▲+0.046Return on capital employed ▲+0.046Operating ROA ▲+0.046Income quality ▲+8.713Tax burden ▼-1.607
Efficiency
Days sales outstanding ▲+12.300Days payables outstanding ▼-4.103Operating cycle ▲+3.800Cash conversion cycle ▲+7.903Capex / Sales ▼-0.004R&D / Sales ▼-0.007
Balance-sheet strength
Current ratio ▲+0.762Net debt / EBITDA ▼-1.628Working capital ▲+571513000.000Invested capital ▲+427301000.000Intangibles / Total assets ▼-0.065
Change over 5 years
Valuation
Market cap ▲+453.5%EV / Sales ▲+32.3%EV / EBITDA ▲+26.7%EV / Op. cash flow ▲+4.929Earnings yield ▲+0.003
Profitability
Return on equity ▼-1.047Return on assets ▲+0.017Return on invested capital ▲+0.108Return on capital employed ▲+0.104Operating ROA ▲+0.079Income quality ▼-18.043Tax burden ▲+0.179
Efficiency
Days sales outstanding ▼-7.477Days payables outstanding ▲+13.256Operating cycle ▼-24.775Cash conversion cycle ▼-38.030Capex / Sales +0.000R&D / Sales ▼-0.038
Balance-sheet strength
Current ratio ▼-0.077Net debt / EBITDA ▼-2.536Working capital ▲+186683000.000Invested capital ▼-502965000.000Intangibles / Total assets ▼-0.132
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2019-05-24 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
Recent news
- 2026-08-18 5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
- 2026-08-12 Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist? Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
- 2026-08-12 Can Amneal''s Kashiv Deal Turn Biosimilars Into a Major Growth Engine? AMRX''s Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
- 2026-08-12 AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now? Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
- 2026-08-11 Amneal (AMRX) Is a Great Choice for ''Trend'' Investors, Here''s Why Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 2026-08-10 Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal''s growth profile into the 2030s BRIDGEWATER, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization.
- 2026-08-07 Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock? Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-08-01 Arkadios Wealth Advisors Takes Position in Amneal Pharmaceuticals, Inc. $AMRX Arkadios Wealth Advisors purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 335,098 shares of the company''s stock, valued at approximately $4,165,000. Arkadios Wealth Advisors owned approximately
- 2026-07-31 AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.
- 2026-07-30 Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript